Literature DB >> 10964115

Recent advances in ischaemic heart disease.

M Cusack1, S Redwood, J Coltart.   

Abstract

There continue to be important developments in the understanding of the pathogenesis of coronary artery disease. Advances have also been made in both the medical and interventional management of patients with ischaemic heart disease. This review has, however, not focused on the wider developments that have occurred in the area of percutaneous intervention. The vast array of new stent designs and other interventional devices have had a considerable impact on the treatment of obstructive coronary disease. In addition it is likely that further developments will be seen in areas such as intracoronary radiotherapy to reduce restenosis after PTCA and in gene therapy to promote angiogenesis in ischaemic myocardium. Both of which will be discussed in a future review of this area.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964115      PMCID: PMC1741717          DOI: 10.1136/pmj.76.899.542

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  50 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.

Authors:  A M Lincoff; R M Califf; K M Anderson; H F Weisman; F V Aguirre; N S Kleiman; R A Harrington; E J Topol
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

3.  Histological findings after transmyocardial laser revascularization.

Authors:  T Krabatsch; F Schäper; C Leder; J Tülsner; U Thalmann; R Hetzer
Journal:  J Card Surg       Date:  1996 Sep-Oct       Impact factor: 1.620

4.  Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research Investigators.

Authors:  D R Ferry; R A O'Rourke; A S Blaustein; M H Crawford; P C Deedwania; P E Carson; C J Pepine; R G Thomas; M A Hlatky; J A Leppo; M K Iwane; R E Kleiger; R G Zoble; H Dai; B K Chow; P W Lavori; W E Boden
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

5.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

6.  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

7.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

8.  Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Authors:  H Toss; B Lindahl; A Siegbahn; L Wallentin
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

9.  Transmyocardial laser revascularization. Histological features in human nonresponder myocardium.

Authors:  N Gassler; H O Wintzer; H M Stubbe; A Wullbrand; U Helmchen
Journal:  Circulation       Date:  1997-01-21       Impact factor: 29.690

10.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

Authors:  P M Ridker; R J Glynn; C H Hennekens
Journal:  Circulation       Date:  1998-05-26       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.